Complexity of Plasmodium falciparum Infections Is Consistent over Time and Protects against Clinical Disease in Tanzanian Children

The complexity of Plasmodium falciparum populations in 21 children was studied in repetitive samples over 4 years in an area of Tanzania where the organism is holoendemic. Genotyping was done by a polymerase chain reaction method that targets three highly polymorphic regions of the merozoite surface...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infectious diseases Vol. 179; no. 4; pp. 989 - 995
Main Authors Färnert, Anna, Rooth, Ingegerd, Svensson, Åke, Snounou, Georges, Björkman, Anders
Format Journal Article Conference Proceeding
LanguageEnglish
Published Chicago, IL The University of Chicago Press 01.04.1999
University of Chicago Press
Oxford University Press
Subjects
Online AccessGet full text
ISSN0022-1899
1537-6613
DOI10.1086/314652

Cover

More Information
Summary:The complexity of Plasmodium falciparum populations in 21 children was studied in repetitive samples over 4 years in an area of Tanzania where the organism is holoendemic. Genotyping was done by a polymerase chain reaction method that targets three highly polymorphic regions of the merozoite surface protein (MSP) 1 block 2, MSP 2, and the glutamine-rich protein. Eight children were repeatedly parasitemic, 5 had scanty parasitemias, and 8 were consistently nonparasitemic. Varying numbers of genotypes were detected in the parasitemic children, but the multiplicity of infection was significantly constant within each child. The children with frequent parasitemias experienced fewer clinical episodes during the study period than those without parasitemias. There was also a tendency for children with more complex infections to experience fewer episodes. The children had consistent parasitologic profiles over the 4 years. Although few subjects were studied and the results will require confirmation, the results suggest that asymptomatic (especially polyclonal) P. falciparum infection protects against clinical disease from new infections.
Bibliography:ark:/67375/HXZ-P7QSSSFQ-4
istex:1FE662CE91C592DB19B0B57C5162EC373C0F1A39
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ISSN:0022-1899
1537-6613
DOI:10.1086/314652